60499-30-1

Basic information

• Product Name: toluene-4-sulfonic acid 1-methylpyrrolidin-3-yl ester
• Synonyms: toluene-4-sulfonic acid 1-methylpyrrolidin-3-yl ester
• CAS NO: 60499-30-1
• Molecular Weight: 255.338
• Mol File: 60499-30-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: toluene-4-sulfonic acid 1-methylpyrrolidin-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: toluene-4-sulfonic acid 1-methylpyrrolidin-3-yl ester(60499-30-1)
• EPA Substance Registry System: toluene-4-sulfonic acid 1-methylpyrrolidin-3-yl ester(60499-30-1)

Safety Data

• Hazardous Substances Data: 60499-30-1(Hazardous Substances Data)

Upstream product

• 13220-33-2 1-methyl-3-pyrrolidinol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 13118-11-1 3-(2-cyclopentyl-2-hydroxy-2-phenylacetyloxy)-1-methylpyrrolidine 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

PROCESS FOR PREPARATION OF GLYCOPYRROLATE INTERMEDIATE

The present invention discloses an improved process for preparation of highly pure cyclopentyl mandelic acid derivative of formula (I), an intermediate of glycopyrrolate, without using hazardous chemicals.

ANTI-FIBROTIC COMPOUNDS

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))